Accessibility Menu
Takeda Pharmaceutical logo

Takeda Pharmaceutical(NYSE) TAK

Market Cap$54.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)+6%
5 Year+27%
1 Year+22%
1 Month+10%
$17.46
+1.28%
+0.22Today
Takeda Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 17.242026-07-24
Takeda Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.52%USD 17.152026-07-17
1 month+9.67%USD 15.722026-06-24
3 month+3.67%USD 16.632026-04-24
Year to date+12.48%USD 15.332025-12-31
1 year+22.31%USD 14.102025-07-24
3 year+27.33%USD 13.542023-07-25
5 year+27%USD 13.582021-07-23
Since inception+5.75%USD 16.302010-05-10

Takeda Pharmaceutical Financials at a Glance

Market Cap

$54.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥4.55T

Net Income (TTM)

¥193.19B

EPS (TTM)

-$0.29

P/E Ratio

-61.33

Dividend

$0.63

Beta (Volatility)

0.32 (Low)

Price

$17.46

Volume

97,356

Open

$17.62

Previous Close

$17.46

Daily Range

$17.43 - $17.62

52-Week Range

$12.99 - $18.90

Estimated Earnings Date

Jul 30, 2026

TAK News

drug development pharmaceutical pharma research researchers doctors

Pharmaceutical tariffs: Which countries does the U.S. import the most from?

Jack CaporalApr 2, 2026
A person counting money in their living room.

One Ultra-Cheap High-Yield Dividend Stock to Buy

David Jagielski, CPADec 22, 2023
researcher

Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris

George Budwell, PhDAug 24, 2023
dividends

2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now

George Budwell, PhDAug 23, 2023
People reviewing financials on a screen.

2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade

David Jagielski, CPANov 16, 2022
Businessman showing chart to co-worker.

3 High-Yielding Dividend Stocks Near Their 52-Week Lows

David Jagielski, CPAOct 19, 2022
People reviewing financials on a screen.

Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years

David Jagielski, CPASep 14, 2022
investor expresses regret

Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes

Alex CarchidiJun 11, 2022
Page 1

TAK: Motley Fool Moneyball Superscore

69

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company operates across a vast international footprint, targeting critical therapeutic areas such as digestive disorders, rare diseases, cancer care, and neurological conditions.

Products and Services
  • Medicines for digestive disorders, rare diseases, and oncology
  • Plasma-derived treatments and neurological condition therapies
  • Well-recognized brands like Entyvio, Adynovate, and Velcade
Growth Outlook
  • Strong pipeline with multiple collaborations enhancing innovation
  • Focus on expanding market presence in Asia and Europe
  • Strategic partnerships expected to drive future revenue growth
Financial Highlights
  • Recent quarterly revenue of 1.11 trillion JPY, showing resilience
  • Trailing twelve months (TTM) revenue of 4.5 trillion JPY
  • Dividend yield of 3.65%, reflecting commitment to shareholder returns
Takeda Pharmaceutical Company Limited has established itself as a leader in the biopharmaceutical industry, with a diverse portfolio that addresses significant health challenges. The company's strategic focus on innovation and partnerships positions it well for future growth. Recent financial performance indicates a solid revenue base, with a commitment to returning value to shareholders through dividends. The ongoing expansion into new markets and therapeutic areas further enhances its growth potential, making it an intriguing option for investors interested in the healthcare sector.
AI Generated • Jul 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

47,029

CEO

Christophe Weber, PhD

Website

www.takeda.com

Headquarters

Tokyo, OS 103-8668, JP

TAK Financials

Key Financial Metrics (TTM)

Gross Margin

58.76%

Operating Margin

10.54%

Net Income Margin

4.26%

Return on Equity

2.61%

Return on Capital

4.51%

Return on Assets

1.24%

Earnings Yield

-1.63%

Dividend Yield

3.66%

Payout Ratio

1.63%

Stock Overview

Market Cap

$54.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.18B

Volume

97.36K

Avg. Volume

3.22M

Financials (TTM)

Gross Profit

¥2.66T

Operating Income

¥495.17B

EBITDA

¥1.37T

Operating Cash Flow

¥986.56B

Capital Expenditure

-¥395.93B

Free Cash Flow

¥590.62B

Cash & ST Invst.

¥597.63B

Total Debt

¥4.90T

Takeda Pharmaceutical Performance Analysis

Takeda Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 29,731,234,709-6.4%
20242024-03-31JPY 29,524,693,129-0.7%
20252025-03-31JPY 30,052,738,4511.8%
20262026-03-31JPY 29,900,176,919-0.5%
Takeda Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-305.1%
Q22025-09-300.6%
Q32025-12-319.0%
Q42026-03-31-8.1%
Takeda Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.7514.8%
20242024-03-31JPY 0.32-57.7%
20252025-03-31JPY 0.22-30.1%
20262026-03-31JPY -0.32N/A
Takeda Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30219.9%
Q22025-09-30-109.6%
Q32025-12-31980.3%
Q42026-03-31-124.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

¥1.11T

+5.8%

Gross Profit

¥543.81B

-19.0%

Gross Margin

48.79%

N/A

Market Cap

$54.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.17M

N/A

Employees

47,029

N/A

Net Income

-¥24.77B

+76.0%

EBITDA

¥157.89B

-12.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

¥597.63B

+47.3%

Total Debt

¥4.90T

+8.6%

Accounts Receivable

¥880.15B

+21.4%

Inventory

¥1.40T

+15.2%

Long Term Debt

¥4.39T

+10.6%

Short Term Debt

¥514.38B

-6.3%

Return on Assets

1.24%

N/A

Return on Invested Capital

3.65%

N/A

Free Cash Flow

-¥26.01B

-115.0%

Operating Cash Flow

¥19.66B

-91.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CAHCardinal Health, Inc.
$229.35+0.58%
BDXBecton, Dickinson and Company
$158.92+1.64%
EWEdwards Lifesciences Corporation
$83.04+0.50%
HLNHaleon plc
$9.94+1.64%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$196.51-0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About TAK

What is the current price of Takeda Pharmaceutical?

Takeda Pharmaceutical is trading at $17.46 per share.

What is the 52-week range for Takeda Pharmaceutical?

Over the past 52 weeks, Takeda Pharmaceutical has traded between $12.99 and $18.90.

How much debt does Takeda Pharmaceutical have?

As of the most recent reporting period, Takeda Pharmaceutical reported total debt of ¥34.42B.

How much cash does Takeda Pharmaceutical have on hand?

Takeda Pharmaceutical reported ¥909.93M in cash and cash equivalents in its most recent financial results.

What is Takeda Pharmaceutical’s dividend yield?

Takeda Pharmaceutical currently has a dividend yield of 3.66%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services